Jeffrey V Lazarus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2211692/publications.pdf

Version: 2024-02-01

41627 2634 46,990 312 51 200 citations h-index g-index papers 326 326 326 57877 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Patient satisfaction with HIV care service in Spain: results from a cross-sectional patient survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 892-898.	0.6	4
2	Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. Digestive and Liver Disease, 2022, 54, 800-804.	0.4	9
3	The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study. Lancet Public Health, The, 2022, 7, e169-e176.	4.7	7
4	The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. Aids, 2022, 36, 423-435.	1.0	8
5	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
6	Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines. The Lancet Global Health, 2022, 10, e142-e147.	2.9	35
7	Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as pointâ€ofâ€care. Liver International, 2022, 42, 309-319.	1.9	7
8	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
9	Integrating Care for Diabetes and Hypertension with HIV Care in Sub-Saharan Africa: A Scoping Review. International Journal of Integrated Care, 2022, 22, 6.	0.1	17
10	Covid-19: An urgent call for global "vaccines-plus―action. BMJ, The, 2022, 376, o1.	3.0	19
11	Editorial: global liver fat accumulation and global healthâ€"towards a sustainable development goal. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 489-490.	1.9	0
12	The mental health crisis during the COVID-19 pandemic in older adults and the role of physical distancing interventions and social protection measures in 26 European countries. SSM - Population Health, 2022, 17, 101017.	1.3	33
13	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	1.9	11
14	A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Communications Medicine, 2022, 2, .	1.9	2
15	A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. Seminars in Liver Disease, 2022, 42, 159-172.	1.8	14
16	Knowledge of liver fibrosis stage among adults with <scp>NAFLD</scp> / <scp>NASH</scp> improves adherence to lifestyle changes. Liver International, 2022, 42, 984-994.	1.9	24
17	A call for advocacy and patient voice to eliminate hepatitis B virus infection. The Lancet Gastroenterology and Hepatology, 2022, 7, 282-285.	3.7	7
18	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	1.8	114

#	Article	IF	Citations
19	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
20	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. The Lancet Gastroenterology and Hepatology, 2022, 7, 552-559.	3.7	25
21	COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Global Health, 2022, 7, e009010.	2.0	29
22	Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries. Vaccine, 2022, 40, 4081-4089.	1.7	43
23	Problems undermining the health-related quality of life of people living with HIV in Spain: a qualitative study to inform the development of a novel clinic screening tool. Health and Quality of Life Outcomes, 2022, 20, .	1.0	4
24	Ten steps to eliminating hepatitis C in hospitals. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 481-483.	8.2	8
25	A call for citizen science in pandemic preparedness and response: beyond data collection. BMJ Global Health, 2022, 7, e009389.	2.0	10
26	Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nature Communications, 2022, 13, .	5.8	201
27	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. Clinical Gastroenterology and Hepatology, 2021, 19, 1451-1458.e4.	2.4	12
28	Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era. Clinical Infectious Diseases, 2021, 73, e1222-e1227.	2.9	30
29	An evaluation of selfâ€management outcomes among chronic care patients in community homeâ€based care programmes in rural Malawi: A 12â€month followâ€up study. Health and Social Care in the Community, 2021, 29, 353-368.	0.7	7
30	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	1.0	28
31	A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 2021, 27, 225-228.	15.2	2,001
32	Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play. Seminars in Liver Disease, 2021, 41, 109-116.	1.8	3
33	A global investment framework for the elimination of hepatitis B. Journal of Hepatology, 2021, 74, 535-549.	1.8	51
34	Micro-elimination: A Key Component of Global Hepatitis C Elimination., 2021,, 247-270.		1
35	A cross-sectional study of the association of age, gender, education and economic status with individual perceptions of governmental response to COVID-19. BMJ Open, 2021, 11, e047310.	0.8	1
36	Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101564.	0.7	11

#	Article	IF	Citations
37	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€ilness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
38	European â€~NAFLD Preparedness Index' — Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	2.6	27
39	Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain. Open Forum Infectious Diseases, 2021, 8, ofab251.	0.4	0
40	Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. International Health, 2021, 13, 399-409.	0.8	41
41	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Scientific Reports, 2021, 11, 9819.	1.6	18
42	Authors' Reply to: Redundancy of Terms in Search Strategies. Comment on "Searching PubMed to Retrieve Publications on the COVID-19 Pandemic: Comparative Analysis of Search Strings― Journal of Medical Internet Research, 2021, 23, e29507.	2.1	0
43	COVID-SCORE Spain: public perceptions of key government COVID-19 control measures. European Journal of Public Health, 2021, 31, 1095-1102.	0.1	12
44	Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study. Lancet HIV,the, 2021, 8, e363-e375.	2.1	32
45	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
46	A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity. Liver International, 2021, 41, 2295-2307.	1.9	16
47	Development of a Clinic Screening Tool to Identify Burdensome Health-Related Issues Affecting People Living With HIV in Spain. Frontiers in Psychology, 2021, 12, 681058.	1.1	6
48	Microâ€elimination of hepatitis C among people living with HIV in Egypt. Liver International, 2021, 41, 1445-1447.	1.9	2
49	SARS-CoV-2 detection by self-testing: A method to improve surveillance programmes. GastroenterologÃa Y HepatologÃa, 2021, 44, 395-397.	0.2	0
50	Defining comprehensive models of care for NAFLD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 717-729.	8.2	72
51	SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties. Lancet, The, 2021, 397, 2234-2236.	6.3	125
52	Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. Journal of Hepatology, 2021, 75, 224-226.	1.8	5
53	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	5.8	67
54	Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. International Journal of Drug Policy, 2021, 96, 103320.	1.6	23

#	Article	IF	CITATIONS
55	Vaccinate fast but leave no one behind: a call to action for COVID-19 vaccination in Spain. Communications Medicine, $2021, 1, .$	1.9	7
56	Pooling samples for hepatitis C RNA detection. The Lancet Gastroenterology and Hepatology, 2021, 6, 608-609.	3.7	2
57	Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. Journal of Hepatology, 2021, 75, 1267-1270.	1.8	24
58	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. International Journal of Drug Policy, 2021, 96, 103424.	1.6	10
59	A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain. Scientific Reports, 2021, 11, 17063.	1.6	11
60	Lessons learned from the first European project on the integration of infectious diseases in testing services, data collection and country responses. BMC Infectious Diseases, 2021, 21, 690.	1.3	2
61	Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-8.	0.6	1
62	NAFLD: Challenges and opportunities to address the public health problem in Latin America. Annals of Hepatology, 2021, 24, 100359.	0.6	20
63	Gulf Cooperation Council states: On the brink of HBV elimination. Liver International, 2021, 41, 2805-2808.	1.9	1
64	Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 2021, 3, 100322.	2.6	109
65	Quality of life in people living with HIV in Romania and Spain. BMC Infectious Diseases, 2021, 21, 898.	1.3	10
66	Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes. Lancet, The, 2021, 398, 1111-1113.	6.3	7
67	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV,the, 2021, 8, e633-e651.	2.1	56
68	Progress towards hepatitis C virus elimination in highâ€income countries: An updated analysis. Liver International, 2021, 41, 456-463.	1.9	81
69	Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. BMJ Open, 2021, 11, e053394.	0.8	1
70	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7
71	What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. Journal of Clinical Medicine, 2021, 10, 5019.	1.0	23
72	Unclear conclusions on SARS-CoV-2 elimination versus mitigation – Authors' reply. Lancet, The, 2021, 398, 1566-1567.	6.3	0

#	Article	IF	CITATIONS
73	COVID-19 vaccine acceptance among adults in four major US metropolitan areas and nationwide. Scientific Reports, 2021, 11, 21844.	1.6	75
74	Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda. BMJ Open, 2021, 11, e047979.	0.8	0
75	Integrating diabetes, hypertension and HIV care in sub-Saharan Africa: a Delphi consensus study on international best practice. BMC Health Services Research, 2021, 21, 1235.	0.9	10
76	HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019. Eurosurveillance, 2021, 26, .	3.9	6
77	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. Revista Espanola De Enfermedades Digestivas, 2021, 114, 5-9.	0.1	1
78	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Scientific Reports, 2021, 11, 24133.	1.6	13
79	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Alimentary Pharmacology and Therapeutics, 2021, 53, 1080-1089.	1.9	19
80	Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda. BMJ Open, 2021, 11, e047979.	0.8	5
81	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	1.8	123
82	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036913.	2.9	19
83	Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV, the, 2020, 7, e59-e68.	2.1	79
84	Securing sustainable funding for viral hepatitis elimination plans. Liver International, 2020, 40, 260-270.	1.9	24
85	Epidemiology of hepatitis C virus infection in a country with universal access to directâ€acting antiviral agents: Data for designing a costâ€effective elimination policy in Spain. Journal of Viral Hepatitis, 2020, 27, 360-370.	1.0	39
86	COVID-SCORE: A global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10). PLoS ONE, 2020, 15, e0240011.	1.1	152
87	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
88	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	6.3	3,928
89	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	6.3	890
90	The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). BMJ Open, 2020, 10, e039724.	ا, 0.8	13

#	Article	IF	Citations
91	Strengthening integration of chronic care in Africa: protocol for the qualitative process evaluation of integrated HIV, diabetes and hypertension care in a cluster randomised controlled trial in Tanzania and Uganda. BMJ Open, 2020, 10, e039237.	0.8	16
92	A letter of solidarity during the COVIDâ€19 pandemic. Liver International, 2020, 40, 2877-2878.	1.9	0
93	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS ONE, 2020, 15, e0235715.	1.1	12
94	Strengthening vaccine confidence during the COVID-19 pandemic: AÂnew opportunity for global hepatitis B virus elimination. Journal of Hepatology, 2020, 73, 490-492.	1.8	5
95	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. The Lancet Gastroenterology and Hepatology, 2020, 5, 948-953.	3.7	24
96	Simplification of Care for Chronic Hepatitis C Virus Infection. Seminars in Liver Disease, 2020, 40, 392-402.	1.8	23
97	Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology and Hepatology, 2020, 5, 927-939.	3.7	28
98	Progress towards elimination goals for viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 533-542.	8.2	118
99	Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa. BMJ Global Health, 2020, 5, e002193.	2.0	10
100	Hepatitis C prevalence in Denmark in 2016â€"An updated estimate using multiple national registers. PLoS ONE, 2020, 15, e0238203.	1.1	20
101	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	6.3	330
102	Correspondence on: "Should we consider a †fourth 90†for tuberculosis?†International Journal of Tuberculosis and Lung Disease, 2020, 24, 631-632.	0.6	0
103	The impact of the COVID-19 pandemic on harm reduction services in Spain. Harm Reduction Journal, 2020, 17, 87.	1.3	35
104	Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. International Journal of Drug Policy, 2020, 80, 102734.	1.6	37
105	Novel health systems service design checklist to improve healthcare access for marginalised, underserved communities in Europe. BMJ Open, 2020, 10, e035621.	0.8	14
106	Keeping governments accountable: the COVID-19 Assessment Scorecard (COVID-SCORE). Nature Medicine, 2020, 26, 1005-1008.	15.2	44
107	NAFLD $\hat{a}\in$ " sounding the alarm on a silent epidemic. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 377-379.	8.2	94
108	Context matters: a qualitative study of the practicalities and dilemmas of delivering integrated chronic care within primary and secondary care settings in a rural Malawian district. BMC Family Practice, 2020, 21, 101.	2.9	4

#	Article	IF	Citations
109	Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. Transplantation Proceedings, 2020, 52, 815-822.	0.3	8
110	A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Services Research, 2020, 20, 249.	0.9	3
111	â€~I don't want anyone to know': Experiences of obtaining access to HIV testing by Eastern European, non-European Union sex workers in Amsterdam, the Netherlands. PLoS ONE, 2020, 15, e0234551.	1.1	6
112	Pandemic publishing poses a new COVID-19 challenge. Nature Human Behaviour, 2020, 4, 666-669.	6.2	188
113	A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB. HIV Medicine, 2020, 21, 403-408.	1.0	0
114	Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infectious Diseases, 2020, 20, 181.	1.3	12
115	The paediatric population: the forgotten element to eliminating hepatitis C virus. The Lancet Gastroenterology and Hepatology, 2020, 5, 334-335.	3.7	0
116	Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease― Journal of Hepatology, 2020, 73, 221-222.	1.8	1
117	Ability to Monitor National Responses to the HIV Epidemic "Beyond Viral Suppression― Findings From Six European Countries. Frontiers in Public Health, 2020, 8, 36.	1.3	2
118	Hesitant or Not? The Association of Age, Gender, and Education with Potential Acceptance of a COVID-19 Vaccine: A Country-level Analysis. Journal of Health Communication, 2020, 25, 799-807.	1.2	174
119	Searching PubMed to Retrieve Publications on the COVID-19 Pandemic: Comparative Analysis of Search Strings. Journal of Medical Internet Research, 2020, 22, e23449.	2.1	18
120	Accelerating the elimination of hepatitis C in Kuwait: An expert opinion. World Journal of Gastroenterology, 2020, 26, 4415-4427.	1.4	4
121	Access to Comprehensive Chagas Disease Care: A Global Effort. , 2020, , 193-212.		1
122	Title is missing!. , 2020, 15, e0234551.		0
123	Title is missing!. , 2020, 15, e0234551.		0
124	Title is missing!. , 2020, 15, e0234551.		0
125	Title is missing!. , 2020, 15, e0234551.		0
126	Title is missing!. , 2020, 15, e0235715.		0

#	Article	IF	Citations
127	Title is missing!. , 2020, 15, e0235715.		0
128	Title is missing!. , 2020, 15, e0235715.		0
129	Title is missing!. , 2020, 15, e0235715.		0
130	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
131	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
132	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
133	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
134	Letter to the Editor: Patientâ∈Reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use. Hepatology, 2019, 70, 443-444.	3.6	1
135	Too many people with viral hepatitis are diagnosed late — with dire consequences. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 451-452.	8.2	28
136	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 2019, 72, 1-10.	1.6	40
137	Excellence in viral hepatitis elimination – Lessons from Georgia. Journal of Hepatology, 2019, 71, 645-647.	1.8	16
138	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	2.9	52
139	THU-403-The consensus hepatitis C cascade of care: Methodology and initial findings from three countries. Journal of Hepatology, 2019, 70, e333-e334.	1.8	1
140	THU-423-Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe. Journal of Hepatology, 2019, 70, e342-e343.	1.8	1
141	FP794HEPATITIS C VIRUS CAN BE ELIMINATED FROM A PREVALENT KIDNEY TRANSPLANT RECIPIENT POPULATION: A SINGLE-CENTRE STUDY IN THE DIRECT-ACTING ANTIVIRALS ERA. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
142	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 579-592.	0.0	2
143	THU-387-Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach. Journal of Hepatology, 2019, 70, e325.	1.8	0
144	We know <scp>DAA</scp> s work, so now what? Simplifying models of care to enhance the hepatitis C cascade. Journal of Internal Medicine, 2019, 286, 503-525.	2.7	69

#	Article	IF	CITATIONS
145	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver International, 2019, 39, 1818-1836.	1.9	44
146	Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF. Health and Quality of Life Outcomes, 2019, 17, 144.	1.0	33
147	France removes hepatitis C treatment prescriber restrictions—But what is the impact of the delay for key populations?. Liver International, 2019, 39, 2418-2419.	1.9	4
148	LBP-11-Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union?. Journal of Hepatology, 2019, 70, e146.	1.8	2
149	PS-065-The global investment case for hepatitis Celimination. Journal of Hepatology, 2019, 70, e39-e40.	1.8	0
150	Patient–provider perspectives on selfâ€management support and patient empowerment in chronic care: A mixedâ€methods study in a rural sub‧aharan setting. Journal of Advanced Nursing, 2019, 75, 2980-2994.	1.5	20
151	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 222-230.	0.2	0
152	Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduction Journal, 2019, 16, 32.	1.3	15
153	Development of a scale for measuring collaboration between physicians and nurses in primary health-care teams. Journal of Interprofessional Care, 2019, 33, 670-679.	0.8	3
154	Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduction Journal, 2019, 16, 20.	1.3	5
155	HIV testing behaviour and HIV prevalence among female sex workers in Ukraine: findings from an Integrated Bio-Behavioural Survey, 2013–2014. Sexually Transmitted Infections, 2019, 95, 193-200.	0.8	8
156	†Virus Carriers†M and HIV testing: navigating Ukraine†HIV policies and programming for female sex workers. Health Research Policy and Systems, 2019, 17, 23.	1.1	9
157	Eliminating hepatitis C in Europe. The Lancet Gastroenterology and Hepatology, 2019, 4, 335-336.	3.7	2
158	Late presentation of chronic hepatitis B virus in Spain: a country with access to therapy. European Journal of Public Health, 2019, 29, .	0.1	0
159	Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV, the, 2019, 6, e869-e877.	2.1	57
160	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	1.9	88
161	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Early Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
162	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 222-230.	0.3	16

#	Article	IF	CITATIONS
163	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del HÃgado (AEEH). GastroenterologÃa Y HepatologÃa, 2019, 42, 579-592.	0.2	25
164	Mining Social Media for Perceptions and Trends on HIV Pre-Exposure Prophylaxis. Studies in Health Technology and Informatics, 2019, 264, 959-963.	0.2	11
165	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Revista Espanola De Enfermedades Digestivas, 2019, 111, 862-873.	0.1	12
166	Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate?. Revista Espanola De Enfermedades Digestivas, 2019, 111, 615-625.	0.1	5
167	Nobody Left Outside (NLO) Checklist: Improving access to healthcare for vulnerable and underserved groups. International Journal of Integrated Care, 2019, 19, 507.	0.1	3
168	Hepatitis C: The beginning of the endâ€"key elements for successful European and national strategies to eliminate HCV in Europe. Journal of Viral Hepatitis, 2018, 25, 6-17.	1.0	65
169	Health Outcomes for Clients of Needle and Syringe Programs in Prisons. Epidemiologic Reviews, 2018, 40, 96-104.	1.3	29
170	Hepâ€CORE: a crossâ€sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. Journal of the International AIDS Society, 2018, 21, e25052.	1.2	17
171	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	3.7	1,241
172	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology and Hepatology, 2018, 3, 125-133.	3.7	128
173	"l don't want anyone to know― HIV testing among Eastern European female sex workers in Amsterdam. European Journal of Public Health, 2018, 28, .	0.1	0
174	Moving to a strong(er) community health system: analysing the role of community health volunteers in the new national community health strategy in Malawi. BMJ Global Health, 2018, 3, e000996.	2.0	21
175	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
176	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
177	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
178	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
179	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
180	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335

#	Article	IF	Citations
181	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
182	Leaving behind pegylated interferonâ€based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by <scp>WHO</scp> . Liver International, 2018, 38, 1902-1905.	1.9	0
183	Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Medicine, 2018, 16, 175.	2.3	51
184	The burden of disease in Spain: Results from the Global Burden of Disease 2016. Medicina ClÃnica (English Edition), 2018, 151, 171-190.	0.1	37
185	Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of Hepatology, 2018, 69, 718-735.	1.8	474
186	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
187	The removal of DAA restrictions in Europe $\hat{a}\in$ One step closer to eliminating HCV as a major public health threat. Journal of Hepatology, 2018, 69, 1188-1196.	1.8	78
188	Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infectious Diseases, 2018, 18, 339.	1.3	9
189	Viral hepatitis: "E―is for equitable elimination. Journal of Hepatology, 2018, 69, 762-764.	1.8	12
190	The hepatitis B epidemic and the urgent need for cure preparedness. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 517-518.	8.2	20
191	Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduction Journal, 2018, 15, 25.	1.3	48
192	Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017. Journal of Hepatology, 2018, 68, S144-S145.	1.8	0
193	Micro-elemination of hepatitis C among patients with congenital bleeding disorders in Slovenia. Journal of Hepatology, 2018, 68, S193-S194.	1.8	5
194	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Seminars in Liver Disease, 2018, 38, 181-192.	1.8	185
195	La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. Medicina ClÃnica, 2018, 151, 171-190.	0.3	113
196	Scaleâ€up of <scp>HIV</scp> selfâ€testing. HIV Medicine, 2018, 19, e72.	1.0	7
197	Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. BMC Public Health, 2018, 18, 16.	1.2	6
198	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157

#	Article	IF	CITATIONS
199	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS ONE, 2018, 13, e0190146.	1.1	9
200	Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013. Epidemiology and Infection, 2017, 145, 1259-1269.	1.0	8
201	Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Medicine, 2017, 15, 92.	2.3	42
202	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. Journal of Hepatology, 2017, 66, S95-S96.	1.8	15
203	Taking the long-view in a personalised approach to HIV care. Lancet HIV, the, 2017, 4, e483-e485.	2.1	3
204	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
205	Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study. Journal of Hepatology, 2017, 66, S408.	1.8	o
206	Implementing the WHO Global Health Sector Strategy on Viral Hepatitis in Denmark – modeling the effects of community-based care on the elimination of HCV by 2030. Journal of Hepatology, 2017, 66, S413-S414.	1.8	0
207	Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 445-446.	8.2	6
208	Micro-elimination – A path to global elimination of hepatitis C. Journal of Hepatology, 2017, 67, 665-666.	1.8	182
209	Commentary on Triasâ€Llimós <i>et al</i> . (2017): Birth cohort researchâ€"an essential tool to guide public health interventions. Addiction, 2017, 112, 259-260.	1.7	6
210	Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. International Journal of Drug Policy, 2017, 47, 47-50.	1.6	21
211	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	1.6	54
212	HMAP, World Hepatitis Day and the bigger health systems picture. Hepatology, Medicine and Policy, $2017, 2, .$	1.7	2
213	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	1.3	33
214	Integrated Control and Management of Neglected Tropical Skin Diseases. PLoS Neglected Tropical Diseases, 2017, 11, e0005136.	1.3	116
215	A people-centred health systems approach to hepatitis C elimination in Europe. European Journal of Public Health, $2016, 26, .$	0.1	0
216	Beyond viral suppression of HIV – the new quality of life frontier. BMC Medicine, 2016, 14, 94.	2.3	279

#	Article	IF	Citations
217	The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002–2014). International Journal of Drug Policy, 2016, 27, 132-137.	1.6	32
218	Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. BMC Infectious Diseases, 2016, 16, 335.	1.3	15
219	Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). Hepatology, Medicine and Policy, 2016, 1, 3.	1.7	4
220	Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatology, Medicine and Policy, 2016, 1, 2.	1.7	27
221	Editor-in-Chief's welcome to Hepatology, Medicine and Policy. Hepatology, Medicine and Policy, 2016, 1, 1.	1.7	6
222	Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012. Eurosurveillance, 2016, 21, .	3.9	3
223	Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croatian Medical Journal, 2016, 57, 442-456.	0.2	14
224	People-centred health services at HIV clinics across Europe: findings from the EuroSIDA clinic survey. International Journal of Integrated Care, 2016, 16, 263.	0.1	1
225	People-centred health services at HIV clinics across Europe: findings from the EuroSIDA clinic survey. International Journal of Integrated Care, 2016, 16, 253.	0.1	0
226	Changes in public attitudes towards confidential adolescent sexual and reproductive health services in Lithuania after the introduction of new legislation: findings from the cross-sectional surveys conducted in 2005 and 2012. BMC Health Services Research, 2015, 15, 360.	0.9	0
227	O125 : A systematic review of hepatitis B and C testing in the countries of the who European region. Journal of Hepatology, 2015, 62, S256.	1.8	0
228	LP31: Strengthening viral hepatitis surveillance in europe: Recommendations from two global hepatitis policy surveys (2013 and 2014). Journal of Hepatology, 2015, 62, S279-S280.	1.8	0
229	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE, 2014, 9, e103345.	1.1	184
230	Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. BMC Infectious Diseases, 2014, 14, S15.	1.3	9
231	Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infectious Diseases, 2014, 14, S14.	1.3	12
232	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. BMC Infectious Diseases, 2014, 14, S18.	1.3	5
233	Factorial validation of the Attitudes toward Women Scale for Adolescents (AWSA) in assessing sexual behaviour patterns in Bolivian and Ecuadorian adolescents. Global Health Action, 2014, 7, 23126.	0.7	10
234	Health service delivery models for the provision of antiretroviral therapy in subâ€6aharan Africa: a systematic review. Tropical Medicine and International Health, 2014, 19, 1198-1215.	1.0	33

#	Article	IF	Citations
235	Hepatitis – a devastating epidemic in Europe. BMC Infectious Diseases, 2014, 14, S1.	1.3	5
236	A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infectious Diseases, 2014, 14, S16.	1.3	55
237	Public expectations concerning confidentiality protection of adolescents' sexual and reproductive health care in Lithuania: Findings of the surveys conducted in 2005 and 2012. European Journal of Contraception and Reproductive Health Care, 2014, 19, 102-107.	0.6	2
238	Preparedness of Lithuanian general practitioners to provide mental healthcare services: a cross-sectional survey. International Journal of Mental Health Systems, 2014, 8, 11.	1.1	8
239	World Hepatitis Day 2013: Know it, Confront it. The Lancet Global Health, 2013, 1, e127-e128.	2.9	2
240	Conclusions from the <scp>HIV</scp> in <scp>E</scp> urope <scp>C</scp> openhagen 2012 <scp>C</scp> onference and ways forward: working together for optimal <scp>HIV</scp> testing and earlier care. HIV Medicine, 2013, 14, 1-5.	1.0	6
241	Primary healthcare providers' views on improving sexual and reproductive healthcare for adolescents in Bolivia, Ecuador, and Nicaragua. Global Health Action, 2013, 6, 20444.	0.7	17
242	Enabling factors for antibiotic prescribing for upper respiratory tract infections: Perspectives of Lithuanian and Russian general practitioners . Upsala Journal of Medical Sciences, 2013, 118, 98-104.	0.4	10
243	Unnecessary injecting of medicines is still a major public health challenge globally. Tropical Medicine and International Health, 2013, 18, 1157-1159.	1.0	10
244	The case for indicator conditionâ€guided <scp>HIV</scp> screening. HIV Medicine, 2013, 14, 445-448.	1.0	29
245	Sexual and reproductive health care for adolescents in Bolivia, Ecuador and Nicaragua: possibilities for improvement from the perspective of primary health care providers. European Journal of Public Health, 2013, 23, .	0.1	0
246	"E―is for everything else, not least for expanding HIV testing in Europe. Bulletin of the World Health Organization, 2012, 90, 634-634.	1.5	2
247	Health Systems Global, the new international society for health systems research. Health Policy and Planning, 2012, 27, 535-540.	1.0	3
248	Dampening the effect of drug resistance in HIV: a leap forward. Lancet Infectious Diseases, The, 2012, 12, 91-92.	4.6	3
249	HIV in men who have sex with men in sub-Saharan Africa. Lancet Infectious Diseases, The, 2012, 12, 505-506.	4.6	6
250	Global Fund investments in harm reduction from 2002 to 2009. International Journal of Drug Policy, 2012, 23, 279-285.	1.6	8
251	Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infectious Diseases, 2012, 12, 229.	1.3	9
252	A study of antibiotic prescribing: the experience of Lithuanian and Russian GPs. Open Medicine (Poland), 2012, 7, 790-799.	0.6	2

#	Article	IF	Citations
253	Key barriers to the use of modern contraceptives among women in Albania: a qualitative study. Reproductive Health Matters, 2012, 20, 158-165.	1.3	17
254	Population mobility and the changing epidemics of <scp>HIV</scp> â€2 in <scp>P</scp> ortugal. HIV Medicine, 2012, 13, 219-225.	1.0	13
255	Making the First Global Society for Health Systems Research Truly Global. Central European Journal of Public Health, 2012, 20, 299-300.	0.4	1
256	HPTN 052 and the future of HIV treatment and prevention. Lancet, The, 2011, 378, 226.	6.3	7
257	Overcoming obstacles to late presentation for HIV infection in Europe. HIV Medicine, 2011, 12, 246-249.	1.0	10
258	The Global Fund's resource allocation decisions for HIV programmes: addressing those in need. Journal of the International AIDS Society, 2011, 14, 51-51.	1.2	16
259	Critical Interactions Between the Global Fund–Supported HIV Programs and the Health System in Ghana. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S72-S76.	0.9	39
260	Confidentiality and parental involvement in adolescent sexual and reproductive health care: A cross-sectional study of Lithuanian general practitioners. Scandinavian Journal of Public Health, 2011, 39, 484-491.	1.2	14
261	HIV in Eastern Europe. , 2011, , 319-336.		2
262	Attitude of Lithuanian Residents to Confidentiality of Adolescent Sexual and Reproductive Health Care. Central European Journal of Public Health, 2011, 19, 210-216.	0.4	4
263	Know your epidemic, know your response: targeting HIV in Asia. Aids, 2010, 24, S95-S99.	1.0	9
264	HIVâ€related restrictions on entry, residence and stay in the WHO European Region: a survey. Journal of the International AIDS Society, 2010, 13, 2-2.	1.2	14
265	HIV and people over 50 years old in Europe. HIV Medicine, 2010, 11, 479-481.	1.0	45
266	Health services strengthening in Africa - research is a key component. Tropical Medicine and International Health, 2010, 15, 1270-1273.	1.0	4
267	Searching PubMed during a Pandemic. PLoS ONE, 2010, 5, e10039.	1.1	7
268	A conceptual and analytical approach to comparative analysis of country case studies: HIV and TB control programmes and health systems integration. Health Policy and Planning, 2010, 25, i21-i31.	1.0	22
269	Improving African health research capacity. Scandinavian Journal of Public Health, 2010, 38, 670-671.	1.2	11
270	Public health in low- and middle-income countries: a glass half full. Journal of Epidemiology and Community Health, 2010, 64, 96-96.	2.0	1

#	Article	IF	CITATIONS
271	Systematic Review of Interventions to Prevent Spread of Sexually Transmitted Infections, Including HIV, Among Young People in Europe. Croatian Medical Journal, 2010, 51, 74-84.	0.2	40
272	HIV epidemics and prevention responses in Asia and Eastern Europe: lessons to be learned?. Aids, 2010, 24, S86-S94.	1.0	20
273	Interactions between critical health system functions and HIV/AIDS, tuberculosis and malaria programmes. Health Policy and Planning, 2010, 25, i1-i3.	1.0	16
274	Sexuality education in Europe: an overview of current policies. Sex Education, 2009, 9, 227-242.	1.5	107
275	HIV epidemics among men who have sex with men in central and eastern Europe. Sexually Transmitted Infections, 2009, 85, 336-342.	0.8	24
276	Men Who Have Sex with Men in Eastern Europe: A Time to Act. Journal of LGBT Health Research, 2009, 5, 1-3.	0.8	2
277	The HIV Epidemic Among Men Who Have Sex with Men in Central and Eastern Europe. Journal of LGBT Health Research, 2009, 5, 33-50.	0.8	3
278	Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002–2006. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 893-902.	0.6	5
279	Monitoring harm reduction in European prisons via the Dublin Declaration. International Journal of Prisoner Health, 2009, 5, 251-255.	0.5	3
280	A multilevel analysis of condom use among adolescents in the European Union. Public Health, 2009, 123, 138-144.	1.4	18
281	Select Barriers to Harm-reduction Services for IDUs in Eastern Europe. Central European Journal of Public Health, 2009, 17, 191-197.	0.4	8
282	Tuberculosis–HIV coâ€infection: policy and epidemiology in 25 countries in the WHO European region. HIV Medicine, 2008, 9, 406-414.	1.0	38
283	Optimal HIV testing and earlier care: the way forward in Europe. HIV Medicine, 2008, 9, 1-5.	1.0	44
284	HIV testing and counselling policies and practices in Europe: lessons learned, ways forward. HIV Medicine, 2008, 9, 30-33.	1.0	4
285	Male circumcision in HIV prevention: some implementation caveats. HIV Medicine, 2008, 9, 327-328.	1.0	4
286	A survey of midwives' views on providing aspects of antenatal care in Estonia. Midwifery, 2008, 24, 399-404.	1.0	2
287	Immunization: Mind the gap. Vaccine, 2008, 26, 6736-6737.	1.7	4
288	The elusive search for an HIV vaccine—And what to do meanwhile. Vaccine, 2008, 26, 6491-6493.	1.7	1

#	Article	IF	CITATIONS
289	Re. Determinants of demand: method selection and provider preference among US women seeking abortion services. Contraception, 2008, 78, 513.	0.8	O
290	Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003—2005. Scandinavian Journal of Public Health, 2008, 36, 183-189.	1.2	7
291	Lithuanian general practitioners' knowledge of confidentiality laws in adolescent sexual and reproductive healthcare: A cross-sectional study. Scandinavian Journal of Public Health, 2008, 36, 303-309.	1.2	7
292	Young Cypriots on sex education: sources and adequacy of information received on sexuality issues. Sex Education, 2008, 8, 237-246.	1.5	9
293	Encouraging Innovation: Ten Research Priorities for Achieving Universal Access to HIV/AIDS Prevention, Treatment and Care in Europe by 2010. Central European Journal of Public Health, 2008, 16, 95-98.	0.4	4
294	Addressing HCV Infection in Europe: Reported, Estimated and Undiagnosed Cases. Central European Journal of Public Health, 2008, 16, 106-110.	0.4	28
295	HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. International Journal of Drug Policy, 2007, 18, 426-432.	1.6	20
296	Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002–2004. International Journal of Drug Policy, 2007, 18, 271-280.	1.6	30
297	HIV/AIDS knowledge and condom use among Somali and Sudanese immigrants in Denmark. Scandinavian Journal of Public Health, 2006, 34, 92-99.	1.2	30
298	Factors affecting attitudes towards medical abortion in Lithuania. European Journal of Contraception and Reproductive Health Care, 2006, 11 , 202-209.	0.6	0
299	HIV/AIDS in Eastern Europe: More Than a Sexual Health Crisis. Central European Journal of Public Health, 2006, 14, 55-58.	0.4	7
300	Improving Family and Community Health in Eastern Europe - the Lifecycle Approcach at WHO. Central European Journal of Public Health, 2006, 14, 109-112.	0.4	1
301	Midwifery at the crossroads in Estonia: attitudes of midwives and other key stakeholders. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 339-348.	1.3	6
302	HIV/AIDS in the transitional countries of eastern Europe and central Asia. Clinical Medicine, 2005, 5, 487-490.	0.8	28
303	Reducing postpartum hemorrhage in Africa. International Journal of Gynecology and Obstetrics, 2005, 88, 89-90.	1.0	24
304	Midwifery at the crossroads in Estonia: attitudes of midwives and other key stakeholders. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 339-348.	1.3	2
305	Introducing Evidence-Based Medicine and guidelines for maternal and newborn care in the Republic of Moldova. Central European Journal of Public Health, 2005, 13, 200-1.	0.4	2
306	ICPD@ten: is reproductive health under fire?. Scandinavian Journal of Public Health, 2004, 32, 476-478.	1.2	2

#	Article	IF	CITATIONS
307	Response to "The HIV/AIDS pandemic: at last good news" editorial by Sven Britton Is the news on HIV/AIDS good?. Scandinavian Journal of Public Health, 2004, 32, 230-231.	1.2	O
308	Observations on Reproductive Health Programs in the Baltic States. International Journal of Gynecology and Obstetrics, 2004, 87, 277-280.	1.0	1
309	Reproductive health: men's business too. Entre Nous: the European Family Planning Magazine, 1999, , 3.	0.0	O
310	The changing role of men since ICPD. Entre Nous: the European Family Planning Magazine, 1999, , 4.	0.0	1
311	Hepatitis delta virus infection prevalence, diagnosis, and treatment in the Middle East: A scoping review. Liver International, 0, , .	1.9	4
312	A call to action to reclaim focus on testing and early treatment for HIV, viral hepatitis, sexually transmitted infections and tuberculosis. International Journal of STD and AIDS, 0, , 095646242211074.	0.5	0